Raltegravir use in special populations
<p>Abstract</p> <p>Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients. It also has an excellent tolerability profile and lacks signif...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-11-01
|
| Series: | European Journal of Medical Research |
| Online Access: | http://www.eurjmedres.com/content/14/S3/43 |